-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In November this year, four policies on the API industry were intensively promulgated, which aroused the attention of the industry
.
Among them, on November 3, the Comprehensive Department of the State Food and Drug Administration issued the "Notice on Activating the Production and Supply Information Collection Module for APIs" for APIs, aimed at strengthening the information infrastructure of APIs, ensuring the safety and stability of China's drug supply chain, and preventing Risk of shortage of medicines
.
On November 9, the National Development and Reform Commission and the Ministry of Industry and Information Technology issued the "Notice on the Implementation Plan for Promoting the High-Quality Development of the API Industry".
The plan proposed to vigorously develop specialty APIs and innovative APIs, encourage superior enterprises to become bigger and stronger, and increase industrial concentration.
.
Adhere to innovation-driven, accelerate the green and low-carbon transformation of APIs, and promote the construction of a new development pattern for the API industry
.
On November 18, the National Anti-Monopoly Bureau was officially listed, and at the same time it issued the "Guidelines for Anti-Monopoly in the Field of APIs" to further clarify the rules of market competition, maintain the order of market competition in the field of APIs, and protect the interests of consumers and the public interest
.
On November 19, the State Drug Administration issued the "Notice of the Center for Drug Evaluation Center to Improve the Review and Approval Progress of APIs", which aims to improve the transparency of drug review and approval, strengthen information disclosure, and respond to social concerns
.
Judging from the above 4 heavy blows, the future life of the API industry will not be easier.
The industry urgently needs to develop in the direction of standardization, green and low-carbon.
It is expected that the industry will face a major reshuffle in the future, with some unqualified raw materials.
Pharmaceutical companies may be eliminated
.
China's APIs have always played an important role in the world.
Since 2020, the status has been further improved due to the impact of the epidemic
.
According to preliminary statistics from the China Chamber of Commerce for Import and Export of Medicines and Health Products, in the first half of 2021, China's export volume of raw materials for pharmaceuticals was US$19.
5 billion, a year-on-year increase of 14%
.
In the context of the promising prospects of the API industry, domestic pharmaceutical companies have continued to move, a series of new or expanded large-scale API projects have started one after another, and under the normalization of centralized procurement, many drugs have won the bid through price-for-volume, and pharmaceutical preparations have been brought The expansion of usage also directly drives the increase in the amount of APIs.
.
At present, centralized procurement has reached the sixth round.
The industry predicts that with the continuous expansion of centralized procurement varieties, more varieties will be incorporated into centralized procurement, which will greatly increase the procurement volume, and the raw materials will also be expanded accordingly
.
According to industry analysts, the recent four documents have been issued in succession, laying the foundation for the supply and price stability of APIs, improving industry transparency, and the development of anti-monopoly work.
The healthy and high-quality development of the API industry has a policy guarantee
.
In the future, China's API industry will enter a stage of high-quality rapid development.
In the future, transformation and upgrading will accelerate, and industry concentration will continue to increase
.
Another securities source pointed out that with policy support, the innovative technology and production level of APIs is expected to be greatly improved, and the domestic API industry is expected to transform towards high value-added specialty APIs.
China's API companies, especially those with synthetic technology Barrier companies will usher in new opportunities
.
The author understands that some pharmaceutical companies have started their transformation in the direction of green development and high value-added products
.
For example, Twinings plans to continue to adhere to the concept of green development and strengthen the resource utilization of by-products in the production process
.
Promote the innovation and upgrading of production technology and promote the green and low-carbon transformation of the industry; the green pharmaceutical industry base project invested and constructed by Tianke Pharmaceutical started commissioning at the end of October.
The project aims to realize the green, intelligent, lean and globalized production of technical materials
.
.
Among them, on November 3, the Comprehensive Department of the State Food and Drug Administration issued the "Notice on Activating the Production and Supply Information Collection Module for APIs" for APIs, aimed at strengthening the information infrastructure of APIs, ensuring the safety and stability of China's drug supply chain, and preventing Risk of shortage of medicines
.
On November 9, the National Development and Reform Commission and the Ministry of Industry and Information Technology issued the "Notice on the Implementation Plan for Promoting the High-Quality Development of the API Industry".
The plan proposed to vigorously develop specialty APIs and innovative APIs, encourage superior enterprises to become bigger and stronger, and increase industrial concentration.
.
Adhere to innovation-driven, accelerate the green and low-carbon transformation of APIs, and promote the construction of a new development pattern for the API industry
.
On November 18, the National Anti-Monopoly Bureau was officially listed, and at the same time it issued the "Guidelines for Anti-Monopoly in the Field of APIs" to further clarify the rules of market competition, maintain the order of market competition in the field of APIs, and protect the interests of consumers and the public interest
.
On November 19, the State Drug Administration issued the "Notice of the Center for Drug Evaluation Center to Improve the Review and Approval Progress of APIs", which aims to improve the transparency of drug review and approval, strengthen information disclosure, and respond to social concerns
.
Judging from the above 4 heavy blows, the future life of the API industry will not be easier.
The industry urgently needs to develop in the direction of standardization, green and low-carbon.
It is expected that the industry will face a major reshuffle in the future, with some unqualified raw materials.
Pharmaceutical companies may be eliminated
.
China's APIs have always played an important role in the world.
Since 2020, the status has been further improved due to the impact of the epidemic
.
According to preliminary statistics from the China Chamber of Commerce for Import and Export of Medicines and Health Products, in the first half of 2021, China's export volume of raw materials for pharmaceuticals was US$19.
5 billion, a year-on-year increase of 14%
.
In the context of the promising prospects of the API industry, domestic pharmaceutical companies have continued to move, a series of new or expanded large-scale API projects have started one after another, and under the normalization of centralized procurement, many drugs have won the bid through price-for-volume, and pharmaceutical preparations have been brought The expansion of usage also directly drives the increase in the amount of APIs.
.
At present, centralized procurement has reached the sixth round.
The industry predicts that with the continuous expansion of centralized procurement varieties, more varieties will be incorporated into centralized procurement, which will greatly increase the procurement volume, and the raw materials will also be expanded accordingly
.
According to industry analysts, the recent four documents have been issued in succession, laying the foundation for the supply and price stability of APIs, improving industry transparency, and the development of anti-monopoly work.
The healthy and high-quality development of the API industry has a policy guarantee
.
In the future, China's API industry will enter a stage of high-quality rapid development.
In the future, transformation and upgrading will accelerate, and industry concentration will continue to increase
.
Another securities source pointed out that with policy support, the innovative technology and production level of APIs is expected to be greatly improved, and the domestic API industry is expected to transform towards high value-added specialty APIs.
China's API companies, especially those with synthetic technology Barrier companies will usher in new opportunities
.
The author understands that some pharmaceutical companies have started their transformation in the direction of green development and high value-added products
.
For example, Twinings plans to continue to adhere to the concept of green development and strengthen the resource utilization of by-products in the production process
.
Promote the innovation and upgrading of production technology and promote the green and low-carbon transformation of the industry; the green pharmaceutical industry base project invested and constructed by Tianke Pharmaceutical started commissioning at the end of October.
The project aims to realize the green, intelligent, lean and globalized production of technical materials
.
